Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Big Brother UK star Aisleyne Horgan-Wallace said she “thought she was going to die” after taking fake Ozempic. Horgan-Wallace ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...